Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar;16 Suppl 1(Suppl1):S412-8.

Impact of pharmaceutical care on quality of life in patients with type 2 diabetes mellitus

Shanmugam Sriram  1 , Lini Elizabeth Chack, Rajeswari Ramasamy, Ali Ghasemi, Thengungal Kochupapy Ravi, Ali Mohammad Sabzghabaee
Affiliations

Impact of pharmaceutical care on quality of life in patients with type 2 diabetes mellitus

Shanmugam Sriram et al. J Res Med Sci. 2011 Mar.

Abstract

Background: Diabetes mellitus has become an international healthcare crisis that requires new approaches to prevent and treat it. The objective of this study was to evaluate the impact of pharmaceutical care on quality of life (QOL) in patients with type 2 diabetes mellitus.

Methods: A prospective study on impact of pharmaceutical care on QOL in patients with type 2 diabetes mellitus was conducted in a private tertiary care teaching hospital in South India for a period of 8 months. Study was done on 120 eligible patients with type 2 diabetes mellitus enrolled randomly in the intervention group (with pharmaceutical care teachings) or the control (without drug related educations). The intervention group patients received pharmaceutical care through diabetes education, medication counseling, instructions on lifestyle that needed modifications (necessary for better drug function) and dietary regulations regarding their prescribed drugs, whereas the control group patients were deprived of any pharmaceutical care till the end of the study. The "Audit of Diabetes Dependent Quality of Life" standard questionnaire was used to assess the relevant parameters (including: Fasting Blood Glucose, HbA1c, Body Mass Index) and to evaluate the impact of the pharmaceutical care on the subjects. Data were analyzed using t-student test.

Results: The intervention group showed an improvement in the quality of life score from -2.156 ± 0.12 at the baseline to -1.41 ± 0.13 at the final interview (p < 0.01). The average HbA1c values decreased from 8.44 ± 0.29% to 6.73 ± 0.21% (p < 0.01). There was a significant decrease in the fasting blood glucose from 195.57 ± 10.10 mg/dl to 107.25 ± 3.70 mg/dl between the baseline and the final interview in the intervention group (p < 0.01). The findings in the diabetes treatment satisfaction score also changed in a similar pattern.

Conclusions: The pharmaceutical care program was effective in improving the clinical outcome and the patients' QOL with type 2 diabetes mellitus.

Keywords: Clinical Pharmacy; Diabetes Mellitus; Pharmaceutical Care; Quality of Life; South India.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interests Authors has no conflict of interests.

References

    1. Gulliford MC, Charlton J. Is relative mortality of type 2 diabetes mellitus decreasing? Am J Epidemiol. 2009;169(4):455–61. - PubMed
    1. The global challenge of diabetes. Lancet. 2008;371(9626):1723. - PubMed
    1. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 2007;125(3):217–30. - PubMed
    1. Ramachandran A, Snehalatha C. Type 2 Diabetes Mellitus - The Epidemic of the 21st century: The Indian Scenario. Int J Diabetes Dev Countries. 1999;19:158–64.
    1. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(Suppl 1):1–68. - PubMed

LinkOut - more resources